Results 21 to 30 of about 22,516 (228)

Development and prevalence of castration-resistant prostate cancer subtypes

Neoplasia: An International Journal for Oncology Research, 2020
Background: Castration-resistant prostate cancer (CRPC) occurs when prostate cancer (CaP) progresses under therapy-induced castrate conditions. Several mechanisms have been proposed to explain this acquired resistance, many of which are driven by ...
Jordan E. Vellky, William A. Ricke
doaj   +1 more source

Reducing TR4 gene expression enhances the sensitivity of prostate cancer cell lines to olaparib by inhibiting the ATM/ATR pathway [PDF]

Journal of Men's Health
Prostate cancer (PC) has risen to become the second most common neoplasm in men, trailing only lung cancer. Individuals with advanced prostate cancer, particularly those who are resistant to androgen deprivation therapy (ADT), also known as castration-
Peng Li, Qiangqiang Xu, Ken Liu, GuanAn Zhao   +3 more
doaj   +1 more source

Dependence of Castration‐Resistant Prostate Cancer (CRPC) Stem Cells on CRPC‐Associated Fibroblasts [PDF]

Journal of Cellular Physiology, 2014
We previously established a role for cancer‐associated fibroblasts (CAF) in enhancing the self‐renewal and differentiation potentials of putative prostate cancer stem cells (CSC). Our published work focused on androgen‐dependent prostate cancer (ADPC) using the conditional Pten deletion mouse model.
Helty, Adisetiyo, Mengmeng, Liang, Chun-Peng, Liao, Joseph H, Jeong, Michael B, Cohen, Pradip, Roy-Burman, Baruch, Frenkel   +6 more
openaire   +2 more sources

Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer [PDF]

Genomics & Informatics, 2018
Because castration-resistant prostate cancer (CRPC) does not respond to androgen deprivation therapy and has a very poor prognosis, it is critical to identify a prognostic indicator for predicting high-risk patients who will develop CRPC. Here, we report
Jong-Lyul Park, Seon-Kyu Kim, Jeong-Hwan Kim, Seok Joong Yun, Wun-Jae Kim, Won Tae Kim, Pildu Jeong, Ho Won Kang, Seon-Young Kim   +8 more
doaj   +1 more source

Hypermethylation of the SRD5A2 promoter region in CRPC.

, 2020
(A) The ratio of SRD5A2 promoter methylation on individual CpG sites in the promoter region in CRPC and benign prostatic tissues in the Local CRPC cohort.
Mary-Ellen Taplin (748901), Xueming Lin (8538264), Aria F. Olumi (3808831), Zhenwei Zhang (528183), Zongwei Wang (694792), Tuo Deng (162685), Shulin Wu (262193), Chin-Lee Wu (205387), Xingbo Long (3356873), Hongbo Wang (587749), Rongbin Ge (3808837)   +10 more
core   +1 more source

Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer

Frontiers in Endocrinology, 2023
BackgroundA huge focus is being placed on the development of novel signatures in the form of new combinatorial regimens to distinguish the neuroendocrine (NE) characteristics from castration resistant prostate cancer (CRPC) timely and accurately, as well
Jingwei Lin, Yingxin Cai, Zuomin Wang, Yuxiang Ma, Jinyou Pan, Yangzhou Liu, Zhigang Zhao   +6 more
doaj   +1 more source

CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER

Медицинский совет, 2016
The article tells about the current problems in the treatment of castrate-resistant prostate cancer. An extensive search for more effective treatments resulted in the development of a number of novel drugs which affect the quality of life of patients as ...
A. A. GRITSKEVICH, S. V. MISHUGIN, A. A. TEPLOV, I. G. RUSAKOV   +3 more
doaj   +1 more source

Sophocarpine inhibits tumor progression by antagonizing the PI3K/AKT/mTOR signaling pathway in castration-resistant prostate cancer [PDF]

PeerJ, 2022
Objective The objective of this study was to investigate the inhibitory effect of sophocarpine on the progression of castration-resistant prostate cancer (CRPC) and the underlying molecular mechanism.
Min Weng, Chenghao Shi, Hui Han, Hengyue Zhu, Yanyi Xiao, Hangcheng Guo, Zhixian Yu, Cunzao Wu   +7 more
doaj   +2 more sources

Targeting TR4 nuclear receptor-mediated p21 downregulation to increase apoptosis for reverse of the Enzalutamide-resistance in prostate cancer [PDF]

Journal of Men's Health
Background: Enzalutamide (enz), also known as MDV3100, is a crucial treatment for advanced Castration-Resistant Prostate Cancer (CRPC). However, many patients develop enz resistance, leading to disease progression and recurrence.
Xuedong Chen, Ken Liu, Qiangqiang Xu, Peng Li, Qingfeng Ji, Junjie Ye   +5 more
doaj   +1 more source

DNA repair pathways-targeted cyclovirobuxine inhibits castration-resistant prostate cancer growth by promoting cell apoptosis and cycle arrest

Translational Oncology, 2023
Background: Castration-resistant prostate cancer (CRPC) is a deadly malignancy without effective therapeutics. Cyclovirobuxine (CVB) can play an anticancer role by inhibiting mitochondrial function, regulating tumor cell apoptosis, dysregulating ...
Ke Gao, Siying Zhu, Qiuju Shao, Yuhong Qi, Chao Zhang, Xiaoshun Li, Jiaheng Guo, Guojun Wu, Hanbing Jiang   +8 more
doaj   +1 more source